期刊文献+

原发性巨球蛋白血症一例

下载PDF
导出
摘要 患者,女,67岁。于2012年4月因“蛋白尿3年,全身浮肿4个月”入院。患者于2009年因突发晕厥就诊某医院,发现蛋白尿,一直行中药治疗,蛋白尿持续存在。
出处 《临床内科杂志》 CAS 2013年第10期713-713,共1页 Journal of Clinical Internal Medicine
  • 相关文献

参考文献4

  • 1Leleu X,Roccaro AM,Moreau AS,et al.Waldenstron macroglobulinemia.Cancer Lett,2008,270:95-107.
  • 2孙丽霞,王金铠.原发性巨球蛋白血症的诊治进展[J].临床荟萃,2006,21(6):439-441. 被引量:6
  • 3张之南,沈悌主编.血液病诊断及疗效标准.第3版.北京:科学出版社.2008.172.
  • 4沈志样,欧阳仁荣.主编.血液肿瘤学.北京:人民卫生出版社,1998.439-445.

二级参考文献20

  • 1Owen RG,Treon SP,Al-Katib A,et al.Clinicopathological definition of Waldenstrom macroglobulinemia:consensus panel recommendations from the Second International Workshop on Waldenstrom Macroglobulinemia[J].Semin Oncol,2003,30(2):110-115.
  • 2Dimopoulos MA,Panayiotidis P,Moulopoulos LA,et al.Waldenstrom macroglobulinemia:clinical features,complications,and management[J].J Clin Oncol,2000,18(1):214-226.
  • 3Dhodapkar MV,Jacobson JL,Gertz MA,et al.Prognostic factors and response to fludarabine therapy in Waldenstrom macroglobulinemia:an update of a US Intergroup Trial(SwoG 5903)[J].Semin Oncol,2003,30(2):220-225.
  • 4Weber DM,Dimopoulos MA,Delasalle K,et al.2-chloredeoxyadenosine alone and in combination for previously untreated Waldenstrom macroglobulinemia[J].Semin Oncol,2003,30(2):243-247.
  • 5Gertz MA,Rue M,Blood E.Rituximab for Waldenstrom macroglobulinemia (E3A98):an ECOG phase Ⅱ pilot study for untreated or previously treated patients[J].Blood,2003,102(suppl 1):148.
  • 6Treon SP,Wasi P,Emmanouilides C,et al.Combination therapy with rituximab and fludarabine is highly active in Waldenstrom macroglobulinemia[J].Blood,2002,100(suppl 1):211.
  • 7Kriangkum J,Taylor BJ,Mant MJ,et al.The malignant clone in Waldenstrom macroglobulinemia[J].Semin Oncol,2003,30(2):132-135.
  • 8Lenoard JP,Coleman M,Matthews JC.Epratuzumab(anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non Hodgkin lymphoma(NHL)-preliminary response data[J].Blood,2002,100(suppl 1):358a.
  • 9Juweid ME.Radioimmunotherpy of B-cell non Hodgkin lymphoma:from clinical trials to clinical practice[J].J Nucl Med,2002,43(11):1507-1529.
  • 10Witzig TE,White CA,Gordon LI,et al.Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade,follicular,or transformed non-Hodgkin lymphoma[J].J Clin Oncol,2003,21(7):1263-1270.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部